120 related articles for article (PubMed ID: 21717787)
1. [High-dose interferon alpha in treatment of patients with malignant melanoma, monitoring of predictive and prognostic biomarkers].
Vanásková J; Grim J; Kopecký J; Kubala E; Filip S
Klin Onkol; 2011; 24(3):180-6. PubMed ID: 21717787
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
4. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
[TBL] [Abstract][Full Text] [Related]
5. Generalized lymphadenopathy mimicking malignant lymph node metastases after interferon-α2b therapy for melanoma.
Yune S; Jang KT; Jung SM; Kim JH; Lee J
Melanoma Res; 2013 Aug; 23(4):336-9. PubMed ID: 23777872
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant therapy for high-risk bulky regional melanoma.
Tarhini AA; Pahuja S; Kirkwood JM
J Surg Oncol; 2011 Sep; 104(4):386-90. PubMed ID: 21858833
[TBL] [Abstract][Full Text] [Related]
8. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
Daud A; Soon C; Dummer R; Eggermont AM; Hwu WJ; Grob JJ; Garbe C; Hauschild A
Expert Opin Biol Ther; 2012 Aug; 12(8):1087-99. PubMed ID: 22694288
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
11. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
Najjar YG; Puligandla M; Lee SJ; Kirkwood JM
Cancer; 2019 Sep; 125(17):3013-3024. PubMed ID: 31067358
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy of cutaneous melanoma: the interferon debate.
Kefford RF
Ann Oncol; 2003 Mar; 14(3):358-65. PubMed ID: 12598338
[TBL] [Abstract][Full Text] [Related]
13. Randomized adjuvant therapy trials in melanoma: surgical and systemic.
Eggermont AM; Gore M
Semin Oncol; 2007 Dec; 34(6):509-15. PubMed ID: 18083374
[TBL] [Abstract][Full Text] [Related]
14. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
15. Adjuvant interferon therapy for malignant melanoma: the debate.
Zhou Q; Zhang XS
Chin J Cancer; 2010 Nov; 29(11):907-13. PubMed ID: 20979689
[TBL] [Abstract][Full Text] [Related]
16. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
Gale DM; Kiley KE
Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
Navid F; Furman WL; Fleming M; Rao BN; Kovach S; Billups CA; Cain AM; Amonette R; Jenkins JJ; Pappo AS
Cancer; 2005 Feb; 103(4):780-7. PubMed ID: 15660397
[TBL] [Abstract][Full Text] [Related]
18. Current management of melanoma: benefits of surgical staging and adjuvant therapy.
McMasters KM; Swetter SM
J Surg Oncol; 2003 Mar; 82(3):209-16. PubMed ID: 12619066
[TBL] [Abstract][Full Text] [Related]
19. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
20. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
Kirkwood JM; Tarhini AA
Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
